Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.
Arcus Biosciences, Inc. (NASDAQ: RCUS) is a cutting-edge, clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment. Founded in 2015 by experienced researchers from the biotechnology and pharmaceutical sectors, Arcus is based in the San Francisco Bay Area, a hub for biotechnological innovation.
Arcus Biosciences focuses on leveraging insights in immunology to create new cancer therapeutics. The company is particularly known for its work on the ATP-adenosine pathway, a significant driver of immunosuppression in the tumor microenvironment. Their aim is to optimize small-molecule immuno-oncology product candidates that could revolutionize cancer treatment.
Arcus has a robust product pipeline that includes several promising candidates such as Domvanalimab, Etrumadenant, AB598, and Casdatifan. These drugs target different aspects of the immune system to either modulate cellular processes in cancer or directly combat tumor growth.
Significant achievements include successful clinical trials for treating various types of cancers, including lung, colorectal, and pancreatic cancers. The company operates through a single segment focused on the development and commercialization of its immunotherapies.
Arcus prides itself on maintaining an internal team of highly skilled professionals rather than outsourcing its research and development efforts. This approach ensures the highest quality and innovation in their drug discovery process.
With ongoing partnerships and collaborations, notably with Gilead Sciences, Arcus is well-positioned to bring its innovative therapies to market, providing new hope for patients with cancer.
Arcus Biosciences (NYSE:RCUS) announced promising results from the interim analysis of the Phase 2 ARC-7 study involving domvanalimab-based combinations for treating metastatic, PD-L1≥50% non-small cell lung cancer (NSCLC). Both combination arms exhibited encouraging clinical activity. The monotherapy arm of zimberelimab displayed response rates comparable to existing anti-PD-1 therapies. No unexpected safety concerns were noted. Arcus and partner Gilead Sciences are set to further explore Phase 3 studies. Upcoming data from ARC-7 will be submitted for presentation at a medical conference.
Arcus Biosciences (NYSE:RCUS) granted stock options to ten new employees, allowing them to purchase a total of 115,800 shares at $24.76 per share, the closing price on June 8, 2021. This grant is part of the Company’s 2020 Inducement Plan approved in January 2020. Arcus is focused on developing cancer therapies, with five molecules in clinical development, including Etrumadenant, AB680, and Domvanalimab, targeting various cancers. The Company's ongoing trials aim to address significant unmet needs in oncology.
Arcus Biosciences (NYSE:RCUS) has granted stock options to 11 new employees for a total of 198,000 shares at an exercise price of $24.55, reflecting the closing price on May 24, 2021. The options were issued under the Company’s 2020 Inducement Plan, approved by the Board in January 2020. This move aims to attract and retain talent within the oncology-focused biopharmaceutical firm, which is developing a diverse portfolio of cancer therapies targeting high unmet medical needs.
Arcus Biosciences (NYSE:RCUS) released initial efficacy and safety data from its Phase 1b/2 ARC-6 study, focusing on mCRPC patients treated with etrumadenant, zimberelimab, and docetaxel. The results showed a promising 41% composite overall response rate (ORR) and a 35% PSA response. Notably, the regimen was well tolerated without significant additive toxicity. Enrollment for the randomized Phase 2 portion has commenced. The data underlines the potential of etrumadenant in advanced prostate cancer treatment. Results will be shared at the upcoming ASCO Annual Meeting.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options to eight new employees, totaling 126,000 shares at an exercise price of $28.86, based on the May 10, 2021 closing price. This issuance was made under the Company’s 2020 Inducement Plan, highlighting its commitment to attracting top talent in oncology therapeutics. The company is actively developing five clinical-stage molecules, including Etrumadenant and Zimberelimab, showcasing its focus on addressing significant unmet needs in cancer treatment.
Arcus Biosciences (NYSE:RCUS) reported robust Q1 2021 results, highlighting significant collaborations and advancements in its clinical pipeline. Revenue rose to $9.5 million, up from $1.8 million year-over-year, driven by Gilead collaborations. Cash reserves increased to $884.9 million. The company is progressing with multiple clinical trials, including the anticipated interim analysis of the ARC-7 trial. Etrumadenant showed promising results in late-line colorectal cancer, doubling survival rates compared to standard therapies. Net loss widened to $72.6 million due to operational growth.
Arcus Biosciences (RCUS) has granted stock options for 140,000 shares to thirteen new employees at an exercise price of $35.77, the closing price on April 23, 2021. This move is in accordance with the 2020 Inducement Plan approved by the Board. The company focuses on developing innovative cancer therapies, currently advancing five molecules in clinical trials, including Etrumadenant and AB680, addressing various types of cancers. Arcus aims to meet significant unmet medical needs in the oncology field.
Arcus Biosciences (NYSE:RCUS) presented data from the ARC-3 study at the AACR Annual Meeting, focusing on etrumadenant's safety and efficacy in mCRC patients. The Phase 1/1b trial showed promising results with a median progression-free survival (PFS) of 4.2 months and overall survival (OS) of 13.6 months, outperforming current standard treatments. Etrumadenant was well tolerated with minimal toxicity. The company is advancing etrumadenant into ARC-9, a Phase 2 study, aiming to address unmet needs in oncology.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options to twelve new employees, totaling 180,200 shares at an exercise price of $30.90, the closing price on April 8, 2021. This action follows the guidelines of the 2020 Inducement Plan approved by the Board of Directors. Arcus is focused on developing innovative cancer therapies, with five molecules currently in clinical development targeting various cancers, including prostate and pancreatic. Notable candidates include Etrumadenant and AB680, which are in different stages of trials.
Arcus Biosciences (NYSE:RCUS) announced the grant of stock options to fourteen new employees, totaling 157,300 shares at an exercise price of $34.45, the closing price on March 23, 2021. This grant aligns with the Company’s 2020 Inducement Plan approved by the Board of Directors in January 2020. The Company is focused on developing innovative cancer therapies and has five molecules in clinical development, including Etrumadenant and Zimberelimab, addressing unmet medical needs in various cancer types.
FAQ
What is the current stock price of Arcus Biosciences (RCUS)?
What is the market cap of Arcus Biosciences (RCUS)?
What does Arcus Biosciences, Inc. do?
Where is Arcus Biosciences located?
When was Arcus Biosciences founded?
What is the core focus of Arcus Biosciences' research?
What are some of Arcus Biosciences' main products?
What types of cancer does Arcus Biosciences target?
Does Arcus Biosciences outsource its research and development?
With whom does Arcus Biosciences have significant partnerships?
What makes Arcus Biosciences unique?
What is the mission of Arcus Biosciences?
